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REVIEW
Abstract: In addition to their role in reverse cholesterol transport, high-density lipoproteins
(HDL) exert several beneficial effects, including the prevention and correction of endothelial
dysfunction. HDL promote endothelium proliferation and diminish endothelial apoptosis; they
play a key role in vasorelaxation by increasing the release of nitric oxide and prostacyclin
through the induction of the expression and the activity of endothelial nitric oxide synthase
and the coupling of cyclooxygenase 2 and prostacyclin synthase. In addition, HDL affect
coagulation, fibrynolisis, platelet adhesion, adhesion molecules, and protease expression, and
they exert antioxidant activity. These effects are achieved at the gene expression level and are
dependent on the activation of several intracellular signaling pathways, including PI3K/Akt,
ERK1/2, PKC, and p38MAPK. The complexity of the signaling pathways modulated by HDL
reflects the different effects of the components of this class of lipoproteins such as
apolipoproteins or lipids on endothelial cell gene expression and the subsequent modulation
of endothelial function observed. The in vivo relevance of these findings to endothelial recovery
during physiological or pathological conditions remains to be addressed; nevertheless, the
results of clinical studies with synthetic HDL, ApoA-I mimetics, and drugs that are becoming
available that selectively affect HDL plasma levels and biological functions support the
importance of the correction of endothelial function by HDL.
Keywords: HDL, endothelium, inflammation, molecular mechanisms, gene expression,
intracellular kinases
Introduction
Numerous clinical and epidemiological studies have demonstrated the inverse
association between high-density lipoprotein cholesterol (HDL-C) and the risk of
coronary heart disease (CHD) events (Gordon and Rifkind 1989; Assmann et al 1996).
Low HDL-C has been identified as the most frequent familial dyslipoproteinemia in
patients with premature myocardial infarction (Genest et al 1992). In angiographic
studies, markers of inflammation had a significant association with CHD, which was
lost upon multivariate analysis taking HDL-C into account (Erren et al 1999). In
several prospective studies, including the prospective ECAT angina pectoris study,
both low serum levels of HDL cholesterol and high serum levels of C-reactive protein
were independent risk factors of a second coronary event in patients with manifest
CHD (Bolibar et al 2000; Ridker 2001). Of note, the results of the Veterans Affairs
High-density Lipoprotein Intervention Trial study showed that raising HDL decreases
the incidence of coronary artery disease events (Robins 2001).
The inverse correlation between HDL cholesterol levels and the risk of CHD is
often explained by the ability of HDL to remove cholesterol from the periphery for
delivery to the liver and excretion in the bile, the process termed reverse cholesterol
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transport (Silver et al 2000). The concept of reverse
cholesterol transport provides the theoretical framework for
understanding body cholesterol homeostasis. Distortion of
reverse cholesterol transport may favor deposition of
cholesterol in the arterial wall and thereby contribute to the
development of arteriosclerosis. The concept of reverse
cholesterol transport is supported by numerous studies in
vitro and in vivo (for a review, see von Eckardstein et al
2001). Several evidences are accumulating to suggest that
in addition to their role in reverse cholesterol transport HDL
positively influence vascular functions including endothelial
responses during atherogenesis (Calabresi 2003). The aim
of this paper is to summarize the existing information on
the role of HDL in preventing and correcting endothelial
dysfunction and to present an overview on the molecular
mechanisms responsible for these effects.
Endothelial dysfunction and
cardiovascular disease
The endothelium is strategically located between the wall
of blood vessels and the blood stream. It senses mechanical
stimuli, such as pressure and shear stress, and hormonal
stimuli, such as vasoactive substances. In response, it
releases agents that regulate vasomotor function, trigger
inflammatory processes, and affect hemostasis. Among the
vasodilator substances produced by the endothelium are
nitric oxide (NO), prostacyclin, various endothelium-derived
hyperpolarizing factors, and C-type natriuretic peptide
(CNP). Vasoconstrictors include endothelin-1 (ET-1),
angiotensin II (Ang II), thromboxane A2 (TXA2), and
reactive oxygen species (ROS). Inflammatory modulators
include intercellular adhesion molecule-1 (ICAM-1),
vascular adhesion molecule-1 (VCAM-1), E-selectin, and
NF-κB. Modulation of hemostasis includes the release of
plasminogen activator, tissue factor inhibitor, von Willebrand
factor, NO, prostacyclin, TXA2, plasminogen-activator
inhibitor-1 (PAI-1), and fibrinogen. The endothelium also
contributes to mitogenesis, angiogenesis, vascular
permeability, and fluid balance (Cines et al 1998).
Endothelial dysfunction was initially identified as
impaired vasodilation to specific stimuli such as acetyl-
choline or bradykinin. A broader understanding of the term
would include not only reduced vasodilation but also a
proinflammatory and prothrombic state associated with
dysfunction of the endothelium.
Endothelial dysfunction has been proposed to be an early
event of pathophysiologic importance in the atherosclerotic
process (Ross 1999; Libby 2002) and provides an important
link between diseases such as hypertension, chronic renal
failure, and diabetes and the high risk of cardiovascular
events that patients with these conditions exhibit. Low NO
bioavailability can up-regulate VCAM-1 in the endothelial
cell layer via induction of NF-κB expression (Khan et al
1996). ROS, CD40 ligand, lectin-like oxidized LDL
receptor-1 (LOX-1) and lipoproteins such as VLDL or
oxidized-LDL (Ox-LDL) also up-regulate endothelial
expression of adhesion molecules (Mach et al 1997; Libby
2002; Norata, Pirillo, et al 2003). The expression of
VCAM-1, ICAM-1, and E-selectin plays a role in the
initiation of the inflammatory process (Ross 1999).
VCAM-1 binds monocytes and T lymphocytes, the first step
of invasion of the vessel wall by inflammatory cells (Libby
2002). NO inhibits leukocyte adhesion (Kubes et al 1991).
Reduction in NO results in induction of monocyte-
chemoattractant protein-1 expression, which recruits
mononuclear phagocytes (Zeiher et al 1995). Monocytes
are then transformed to lipid-loaded foam cells. Ox-LDL,
for example, are scavenged through LOX-1 (Yoshida et al
1998), which is highly expressed in blood vessels in
hypertension, diabetes, and dyslipidemia (Mehta and Li
2002). Ox-LDL trigger a variety of actions: they reduce
eNOS (endothelial nitric oxide synthase) expression (Mehta
and Li 2002) and further stimulate adhesion molecule
expression (Libby 2002), apoptosis (Norata et al 2002), and
release of proinflammatory prostaglandins (Norata, Pirillo,
et al 2004) (Figure 1).
As the atherosclerotic plaque progresses, growth factors
secreted by macrophages in the plaque stimulate vascular
smooth muscle cell growth and interstitial collagen synthesis
(Libby 2002). The event that initiates the majority of
myocardial infarctions is the rupture of the fibrous cap of
the plaque, inducing thrombus formation. Decreased NO
and oxidative excess may activate matrix metalloproteinases
(MMP) (Eberhardt et al 2000; Uemura et al 2001), namely
MMP-2 and MMP-9, which weaken the fibrous cap.
Endothelial NOS has been indicated as the main enzyme
that contributes to NO production in the arterial wall
(Kawashima and Yokoyama 2004). Experimental studies in
vitro have revealed that NO from eNOS constitutes an anti-
atherogenic molecule and that a deficiency of eNOS
accelerates atherosclerotic lesion formation in eNOS
knockout mice (Kawashima and Yokoyama 2004).
Nevertheless, under conditions in which vascular tissue
levels of tetrahydrobiopterin (BH4), a cofactor for NOS,
are deficient or lacking, eNOS becomes dysfunctional andVascular Health and Risk Management 2005:1(2) 121
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produces superoxide rather than NO. eNOS overexpression
with hypercholesterolemia may promote atherogenesis via
increased superoxide generation from dysfunctional eNOS
(Ozaki et al 2002). Thus, eNOS may have 2 faces in the
pathophysiology of atherosclerosis depending on tissue BH4
metabolisms.
Recent works indicate that vascular inflammatory
responses can be limited by antiinflammatory
counteregulatory mechanisms that maintain the integrity and
homeostasis of the vascular wall (Uyemura et al 1996; Mallat
et al 1999). These mechanisms include antiinflammatory
signals such as HDL (Tedgui and Mallat 2001).
HDL effects on the endothelium
Several effects account for the endothelial protection by
HDL, including: the control of cell proliferation; the
inhibition of apoptosis; the modulation of the secretory
functions; the regulation of coagulation, fibrinolysis, and
platelet adhesion; and the inhibition of inflammatory
processes (Table 1).
HDL and cell proliferation
Rapid regeneration through the migration and proliferation
of endothelial cells as well as diminished apoptosis have
been described as key mechanisms in preventing endothelial
damage by HDL. HDL stimulate the proliferation of bovine
(Cohen et al 1982) and human endothelial cells (Darbon et
al 1986), and enhance endothelial cell migration (Murugesan
et al 1994). Initially, it was proposed that apolipoproteins
A-I and C-I were responsible for the mitogenic effects
(Tournier et al 1984; Darbon et al 1986); latest data suggest
that lysosphingolipids, namely sphingosine 1-phosphate
(S1P), sphingosylphosphorylcholine (SPC), and lyso-
sulfatide (LSF), could also enhance endothelial cell
proliferation (Nofer et al 2000; Kimura et al 2001).
Apart from the mitogenic activity, HDL prevent
endothelial cell death. Suc et al (1997) showed that both
HDL and apolipoprotein A-I diminish the induction of
cell death by Ox-LDL. This activity was not related to
the interaction between these two lipoproteins or to
Figure 1 Effects of pro-atherogenic factors on the vascular wall and biological actions of HDL (high-density lipoproteins) on the endothelium. ET-1 (endothelin-1),
AngII (angiotensin II), TXB2 (tromboxane B2), VLDL (very low-density lipoprotein), IL-6 (interleukin 6), TNF-α (tumor necrosis factor alpha), LPS (lipopolysaccharides),
NO (nitric oxide), PGI2 (prostacyclin), MCP-1 (monocyte chemoattractant protein-1), ROS (radical oxygen species), Ox-LDL (oxidized low-density lipoprotein)
promote endothelial dysfunction by inducing adhesion molecule expression and chemotactic factor release. Once recruited, monocytes migrate and differentiate to
macrophages in the vascular wall. Activated endothelium can also promote the migration and proliferation of smooth muscle cells. Both macrophages and smooth
muscle cells scavenge Ox-LDL and become foam cells. HDL interact with endothelium (1) and induce NO and prostacyclin release (2a and 2b). HDL, directly and via
NO and PGI2, can inhibit chemokine secretion (3) and adhesion molecule expression (4). In addition, HDL decrease oxygen radical production (5) and smooth muscle cell
migration and proliferation (6). These mechanisms counteract the progression of atherosclerosis in the vascular wall.
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antioxidative properties of HDL. The inhibition of death of
endothelial cells by HDL or apolipoprotein A-I (ApoA-I) was
most evident after 24-h incubation. The antiapoptotic effect
of HDL was abolished by protein synthesis inhibitors. Thus,
it seems that weakening of the cytotoxic effect of
Ox-LDL in the presence of HDL or ApoA-I is related to the
expression of still unknown factors that prevent cell death.
Also, triglyceride-rich lipoproteins have been shown to
promote endothelial cell death (Norata, Pirillo, et al 2003),
and HDL reduce endothelial necrosis induced by remnants
of triglyceride-rich lipoproteins (Speidel et al 1990). In
addition, Sugano et al (2000) found protective effects of
HDL and ApoA-I against endothelial apoptosis induced by
tumor necrosis factor alpha (TNF-α). HDL also prevent
endothelial cell damage and necrosis resulting from the
activation of the complement system. The C5a–C9 terminal
complement complex was shown to be inversely correlated
with HDL-C, but not total cholesterol, in dyslipidemic
subjects (Pasqui et al 2000). Rosenfeld et al (1983) have
shown that HDL inhibits complement-mediated cell lysis.
HDL and vascular tone
Several clinical studies have demonstrated a close
association
 between plasma levels of HDL and endothelium-
dependent flow-mediated
 dilation (O’Connell and Genest
2001). Recently, administration of reconstituted HDL
 was
shown to restore abnormal endothelial function in
hypercholesterolemic
 men (Spieker et al 2002). Several
mechanisms underlying the effects of HDL on
 endothelial
reactivity have been suggested, including synthesis
 of
vasorelaxing prostanoids such as prostacyclin (PGI2) as well
as activation
 of eNOS via SR-BI (Yuhanna et al 2001).
Incubation of cultured endothelial cells with HDL activates
eNOS in a process that involves the binding of ApoA-I to
the
 scavenger receptor-BI (SR-BI) (Yuhanna et al 2001;
Mineo et al 2003). However, eNOS is not activated
 by lipid-
free ApoA-I. A recent study showed that lysosphingolipids
present in HDL are responsible for these effects (Nofer et
al 2004), while ApoA-I is fundamental for the binding to
the membrane of endothelial cells.
PGI2 is a potent endothelium-derived vasodilator
 that
binds IP receptors on vascular smooth muscle cells (SMC)
and acts synergistically
 with NO to induce smooth muscle
relaxation. PGI2 is synthesized from arachidonate derived
from phospholipids of cellular membranes
 or from
exogenous sources as phospholipids and cholesteryl
 esters
present in circulating lipoproteins. The enzyme responsible
for
 PGI2 production is cyclooxygenase (Cox), which exists
Table 1 HDL effects on the endothelium
Mimicked Mimicked by
HDL  by ApoA-I  lysosphingolipids Key references
Cell proliferation
↑ proliferation Yes Yes Darbon et al 1986
↓ apoptosis Nofer et al 2000
Vascular tone
↑ NO No Yes Yuhanna et al 2001
Nofer et al 2004
↑ PGI2 Yes ? Pomerantz et al 1985
Norata, Pirillo, et al 2004
↓ endothelin 1 ? ? Unoki et al 1999
↑ CNP ? ? Sugiyama et al 1995
Coagulation, fibrinolysis, platelet adhesion
↓ factor X activation Yes ? Carson 1981
↓ tissue factor ? ? Kaneko et al 1994
↓ PAF ? ? Sugatani et al 1996
↓ prothrombinase complex Yes ? Epand et al 1994
↑ activated protein C and protein S ? ? Griffin et al 1999
Inflammation
↓  VCAM-1  No Yes Ashby et al 1998
↓ ICAM-1 ? ? Barter et al 2004
↓ E-selectin ? Yes Nofer et al 2003
↓ MMP-9 ? ? Xu et al 1999
↓ ADAMT-s 1 ? ? Norata, Bjork, et al 2004
↑ TGF-β2 No Yes Norata et al 2005
Abbreviations are listed at the end of the paper.Vascular Health and Risk Management 2005:1(2) 123
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as 2 different isoforms: a constitutive form (Cox-1) and an
inducible form (Cox-2). Cox-2 has been implicated in
several inflammatory processes including the induction of
PGE2 (Norata, Pirillo, et al 2004) a proinflammatory prosta-
glandin that modulates MMPs production in the athero-
sclerotic plaque (Cipollone et al 2001).
Incubation of cultured endothelial cells with HDL causes
a dose-dependent increase of PGI2 release, which is
prevented by a Cox-2 inhibitor, suggesting a major role of
this enzyme in HDL-mediated PGI2 synthesis; indeed, HDL
have shown to induce Cox-2 expression (Norata, Callegari,
et al 2004). Delipidated HDL apolipoproteins
 also enhance
PGI2 production but to a lower extent than intact HDL
(Pomerantz et al 1985). This suggests that different
mechanisms could account for this effect, including the
possibility that HDL can provide endothelial cells with
arachidonate, which then acts as substrate for Cox-mediated
PGI2 synthesis (Pomerantz et al 1985).
The role of Cox-2 in cardiovascular disease is of great
interest, and several clinical trials have reported that selective
Cox-2 inhibitors can increase the relative risk of myocardial
infarction (Juni et al 2004; Furberg et al 2005), probably by
decreasing prostacyclin production (McAdam et al 1999).
Thus, it will be of interest to investigate whether HDL-
dependent Cox-2 induction and prostacyclin release can in
part rescue from Cox-2 inhibitors side effects, and whether
subjects with high HDL levels are less susceptible to the
coronary side effects of Cox-2 inhibitors.
HDL also affect endothelin-1 (ET-1) synthesis (Hu et al
1994). ET-1 is a potent vasoconstrictor peptide that binds
to
 specific G protein-coupled receptors on SMCs to reverse
the
 response to NO. Previous studies have shown that
subphysiological concentrations of native HDL increases
ET-1 production in endothelial cells (Hu et al 1994). These
findings are in contrast with those of a study where
incubation of human endothelial cells cultured with HDL
on a 2-chamber
 model system (a model reproducing the
physiological state where
 ET-1 is released toward the
underlying intimal smooth muscle
 in a polar fashion)
inhibited the secretion of ET-1 on
 the opposite side of the
culture on which they where applied (Unoki et al 1999),
suggesting that HDL may indeed prevent the vasoconstrictor
effects
 of ET-1.
Finally, HDL was shown to modulate the synthesis of
CNP, which causes vasodilatation, inhibits proliferation of
smooth muscle cells, and inhibits ET-1 secretion (Sugiyama
et al 1995). Moreover, suppression of CNP synthesis in the
presence of Ox-LDL is antagonized by HDL.
HDL, coagulation, fibrinolysis, and
platelet adhesion
In contrast to atherogenic lipoproteins, like LDL and very
low-density lipoprotein (VLDL), which stimulate both the
secretion of tissue factor (TF) and the activation of extrinsic
tenase, HDL per se does not stimulate the secretion of TF
from endothelial cells or monocytes (Kaneko et al 1994).
TF synthesis stimulated by VLDL is rather inhibited by HDL
(Rosenson and Lowe 1998). Furthermore, HDL inhibit
thrombin-induced human endothelial TF expression through
inhibition of RhoA and activation of PI3K but not Akt/eNOS
(Viswambharan et al 2004). In addition, HDL antagonize
the activation of factor X induced by extrinsic tenase (Carson
1981). Besides HDL, ApoA-I also inhibits the activation of
factor X. Recent studies have shown that the inhibitory effect
of HDL may be related to the presence of tissue pathway
factor inhibitor (TPFI) in this lipoprotein (Lesnik et al 1993).
Both HDL and ApoA-I inhibit the calcium ionophore-
induced production of the pro-thrombinase complex on the
surface of platelets (Epand et al 1994). HDL may affect the
blood coagulation process via the regulation of activated
protein C (APC), which is the crucial element regulating
blood coagulation by the proteolytic inactivation of Va and
VIIIa factors. The anticoagulatory effect of APC is enhanced
by protein S. HDL augment APC-induced inactivation of
Va and VIIIa factors (Griffin et al 1999). HDL also augment
the activity of protein S to stimulate APC. This activity of
HDL may arise from anticoagulants such as cardiolipin
and phosphatidylethanolamine, which are present in
these lipoproteins. It has been shown that not only
coagulation but also fibrinolysis is regulated by HDL.
Hypercholesterolemia and hypertriglyceridemia are
associated with increased secretion of PAI-1 from
endothelial cells (Stiko-Rahm et al 1990; Norata, Pirillo, et
al 2003). By contrast, HDL cholesterol levels are negatively
correlated with plasma levels of PAI-1 and tissue
plasminogen activator (tPA) (Juhan-Vague et al 1996). This
correlation may reflect the in vitro inhibitory effect of HDL
on tPA and PAI secretion by the endothelium (Ren and Shen
2000). Of note, when HDL are oxidized, the resulting
Ox-HDL have been reported to induce PAI-1 mRNA
expression and protein release in endothelial cells via a
p38MAPK-dependent pathway that promotes mRNA
stabilization (Norata, Banfi, et al 2004).
In addition to coagulation and fibrinolysis, HDL also
affect platelet adhesion. NO and prostacyclin have an
antitrombotic effect besides being regulators of the vascular
tone. HDL inhibit agonist-induced production of platelet-Vascular Health and Risk Management 2005:1(2) 124
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activating factor (PAF), a bioactive phospholipid that
stimulates cell adhesion, platelet aggregation, and vascular
permeability in endothelial cells (Sugatani et al 1996). Von
Willebrand factor (vWF) is another protein expressed by
endothelial cells that plays an essential
 role in platelet
adhesion and aggregation; the circulating vWF
 levels are
inversely correlated with plasma HDL (Conlan et al 1993),
suggesting
 that HDL may inhibit vWF production.
Therefore, by modulating
 the production/activity of a variety
of endothelium-derived
 factors such as NO, PGI2, PAF,
and vWF, HDL may affect both
 vascular tone and
thrombogenicity.
HDL, angiogenesis, and cell migration
Two new aspects of the interaction between HDL and
endothelial cells are stimulation of angiogenesis and cell
motility and migration. An in vitro model of human
 coronary
artery endothelial cell (HCEC) tube formation on a
 matrix
gel has been used to explore the possible angiogenic effect
of HDL (Miura et al 2003). The results have shown that
HDL induce angiogenesis and have identified Ras as a key
player in the
 angiogenic action of HDL (Miura et al 2003).
The signaling pathway in HDL-induced
 tube formation is
through pertussis toxin (PTX)-sensitive G-protein coupled
receptors (GPCRs) and may be partly
 through receptors for
S1P such as EDG-1 and EDG-3 (Miura et al 2003). This
model
 assumes that lipoproteins induce angiogenic signals
through
 PTX-sensitive GPCRs. HDL signaling through
cholesteryl ester donation is an exciting
 possible route to
the induction of angiogenesis. The scavenger
 receptor
SR-BI mediates the selective cellular uptake of cholesterol
from HDL. Consistent with this idea is the observation that
HDL maintains the appropriate cellular localization of
eNOS
 by replenishing endothelial cellular membranes
with cholesteryl
 esters in an SR-BI–dependent fashion
(Uittenbogaard et al 2000).
Endothelial genes implicated in angiogenesis and cell
proliferation include matrix-degrading proteases. Proteases
including MMPs have been shown to play a central role in
endothelial dysfunction (Libby 2002). HDL inhibit MMP-9
expression induced by Ox-LDL in monocytes (Xu et al
1999) and the expression of ADAMTs-1 induced by
lipopolysaccharide (LPS) on TNF-α in endothelial cells
(Norata, Bjork, et al 2004).
ADAMTS-1, a disintegrin and metalloproteinase with
thrombospondin motif, has been shown to inhibit endothelial
cell proliferation by direct binding and sequestration of
vascular endothelial growth factor (Luque et al 2003). It is
thus possible that HDL can influence angionenic processes
through proteases modulation (Norata, Pellegatta, et al
2003).
Although it is not clear whether HDL in its relation to
angiogenesis
 induces the progression of atherosclerosis, the
strong and specific
 angiogenic effect of HDL deserves
attention in the development
 of therapeutic strategies to
elevate plasma levels of these
 lipoproteins.
Control of the inflammatory response
As mentioned above, endothelial dysfunction promotes
adhesion of leukocytes to endothelial cells sustaining the
inflammatory processes during atherogenesis. Interaction
of monocytes with endothelial cells is mediated by adhesion
molecules located on the surface of these cells, which
include VCAM-1, ICAM-1, and E-selectin. VCAM-1 and
ICAM-1 mediate adhesion of mononuclear cells, including
monocytes and lymphocytes. E-selectin enables tethering
and rolling of monocytes and lymphocytes on the surface
of endothelial cells. All three adhesion molecules are
abundantly expressed in the atherosclerotic plaque (van der
Wal et al 1992; Libby 2002).
Expression of VCAM-1 is induced by lysophosphat-
idylcholine present in Ox-LDL and by products of lipolysis
(Kume et al 1992; Saxena et al 1992). Expression of VCAM-
1, ICAM-1, and E-selectin is induced also by cytokines such
as TNF-α, interleukin-1 (IL-1), and LPS (Libby 2002;
Norata, Bjork, et al 2004). HDL inhibits the interaction of
monocytes with endothelial cells and smooth muscle cells
as well as the adhesion of monocytes to endothelial cells
induced by Ox-LDL (Barter et al 2002). Recent studies have
shown that cytokine-induced expression of VCAM-1,
ICAM-1, and E-selectin is inhibited by HDL (Cockerill et
al 1995; Ashby et al 1998; Nofer et al 2003; Barter et al
2004). The most pronounced inhibition of the expression
of these proteins was observed at physiological HDL
concentrations. Inhibition of VCAM-1 and E-selectin
expression on endothelial cells is also induced by
reconstituted HDL and depends strongly on the phospholipid
composition of reconstituted particles as the inhibitory
effects were not exerted by lipid-free apoproteins A-I and
A-II (Ashby et al 1998; Calabresi et al 2003; Nofer et al
2003). Because the inhibitory effect of HDL is observed
even after removal of these lipoproteins from the endothelial
cell culture, it seems not to be related to the scavenging of
free radicals by antioxidants contained in HDL.
HDL has also been shown to affect cytokines,
chemokine, and chemokine receptor expression; using aVascular Health and Risk Management 2005:1(2) 125
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cDNA microarray approach, it has been shown that under
basal conditions, transforming growth factor-β2 (TGF-β2)
is the only gene within a panel of 96 genes involved in
inflammation that is significantly induced upon incubation
with HDL in endothelial cells (Norata et al 2005). The effect
of HDL is specific for TGF-β2, as neither TGF-β1 nor
TGF-β3 expression is modulated by HDL. TGF-β possesses
antiinflammatory properties and stabilizes the plaque
(Grainger 2004), thus suggesting a novel target for the
antiatherosclerotic effect of HDL. Also, IL-18 receptor and
MIP1β expression appear to be modulated by HDL (Norata
et al 2005), but the relevance of this finding needs further
investigation.
Signaling pathways modulated by
HDL
Several intracellular signaling pathways account for the
effects of HDL on the endothelium (see Figure 2 and
Table 2). Both ApoA-I and the lysosphingolipids SPC, LSF,
and sphingosine 1-phosphate present in the HDL are
responsible for intracellular signaling activation. ApoA-I
binding to the scavenger receptor-BI (SR-B1) is required
for HDL activation of eNOS (Yuhanna et al 2001); however,
eNOS is not activated by lipid-free ApoA-I. This discrepancy
was elegantly solved by Nofer et al (2004), which showed
that the interaction of ApoA-I with SR-B1 is required for
localizing the HDL particles at the membrane level where
lysosphingolipids interact with specific receptors as
EDG1/3 (also called S1P3) activating several intracellular
signaling cascades. Moreover, deficiency of the lyso-
phospholipid receptor S1P3 (also known as LPB3 and
EDG3) abolishes the vasodilatory effects of SPC, S1P, and
LSF and reduces the effect of HDL by approximately 60%.
In endothelial cells from S1P3-deficient mice, Akt
phosphorylation, and HDL-dependent calcium increase is
severely reduced. In vivo, intra-arterial administration of
HDL or lysophospholipids lowered mean arterial blood
pressure in rats (Nofer et al 2004). A second mechanism
has been proposed by Mineo et al (2003), which suggests
that HDL via interaction with SR-B1 activate a tyrosine
kinase most likely belonging to the src family kinase that
phosphorylate both Akt and MAPK. The PI3K/Akt pathway
plays a central role in the modulation of HDL-induced eNOS
expression and activity (Mineo et al 2003; Nofer et al 2004).
The activation of the PI3K/Akt pathway by HDL also
maintains mitochondrial integrity by inhibiting cytochrome C
Figure 2 Intracellular signaling pathways activated by high-density lipoprotein (HDL). HDL interact with several membrane proteins, including scavenger receptor-B1
(ApoA-I), EDG1/3 G-coupled receptor (lysosphingolipids S1P, SPC, and LSF) and other putative receptors LRP8 (ApoE), GpIIa/IIIb, CD36 or membrane proteins,
caveolin-1, thus resulting in the phopshorylation of several kinases, MAPK, PI3K/Akt, PCK, p38MAPK, and the modulation of transcription factor activity.
(Abbreviations are listed at the end of the paper.)
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release, caspase 3 and 9 activation, and apoptosis (Nofer,
Levkau, et al 2001). PI3K/Akt activation by HDL has also
been involved in the modulation of the expression of TGF-β2
(Norata et al 2005), a cytokine with antiinflammatory
properties (Mallat and Tedgui 2002). HDL have been shown
to activate also the protein kinase network Raf-1, MEK1/2,
and ERK1/2 (Nofer, Junker, et al 2001; Norata, Callegari,
et al 2004) that is responsible for the cell cycle entry and
for eNOS activation (Nofer, Junker, et al 2001; Mineo et al
2003). ERK1/2 activation leads to the expression of cyclin
D1 and c-fos, resulting in the phosphorylation of the
retinoblastoma protein (pRb), which initiates the progression
of the cell cycle (Nofer, Junker, et al 2001).
The activation of other signaling pathways has been
implicated in HDL-dependent endothelial cell proliferation.
Initially, it was proposed that HDL-induced proliferation
occurs through a protein kinase
 C-mediated pathway, and
HDL apolipoproteins were required for
 this effect (Darbon
et al 1986). More recent data suggest that the mitogenic
effect
 of HDL is mediated by a rise in intracellular pH and
calcium (Tamagaki et al 1996), initiated by phospholipase
C activation (Honda et al 1999), and that the lipid fraction
of HDL is responsible for the rise of intracellular calcium.
These observations suggest that activation of two different
signaling pathways
 by HDL apolipoproteins and lipids may
ultimately enhance proliferation
 of endothelial cells.
Furthermore, the rise in calcium and subsequent activation
of calcium/calmodulin kinase has been implicated in the
activation of the PI3K/Akt pathway leading to increased
eNOS expression and activity (Nofer et al 2004). HDL also
induce the phosphorylation of p38MAPK, which is
implicated in the activation of CREB and subsequent HDL-
dependent Cox-2 induction and prostacyclin release in
endothelial cells (Norata, Callegari, et al 2004).
Of interest, studies have shown that HDL can modulate
the activity of proteins present in plasma membrane
microdomains, known as caveolae, including eNOS and PGI
synthase (PGI-S) (Frank et al 2003). These effects are
achieved both through the maintenance of cholesterol
content in caveolae for eNOS (Uittenbogaard et al 2000;
Everson and Smart 2001) and the phosphorylation of
caveolin1 (the main protein of the caveolae) and subsequent
PGI-S shuttling and Cox-2 coupling in the perinuclear area
of endothelial cells (Norata, Callegari, et al 2004).
Despite the activation of all these intracellular signaling
pathways, the molecular mechanisms by which HDL exert
their antiinflammatory effects are poorly understood. As the
activation of the nuclear factor kappa B (NF-κB) is
responsible for TNF-α–dependent adhesion molecule
expression, it has been proposed that it may act by inhibiting
NF-κB activation. HDL block the TNF-α–induced nuclear
translocation and DNA binding of NF-κB by interrupting a
sphingosine kinase signaling pathway upstream of NF-κB
activation (Xia et al 1999) and inhibiting NF-κB and AP-1
Table 2 The HDL-induced intracellular signaling
Signaling type Resulting effect Key references
Membrane interaction
Interaction with SR-B1 Akt, eNOS phosphorylation Yuhanna  et al 2001
Interaction with EDG1/3 Akt, eNOS phosphorylation Nofer et al 2004
Interaction with LRP8 eNOS phosphorylation Riddell 1999
Interaction with GpIIa/IIIb Possible antagonism Nofer 1998
Interaction with caveolae eNOS phosphorylation Uittenbogaard et al 2000
PGI-synthase shuttling Norata, Callegari, et al 2004
Kinase phosphorylation
MEK1/2-ERK1/2 eNOS phopshorylation Mineo et al 2003
Cell cycle entry Nofer, Junker, et al 2001
PI3K/Akt eNOS phopshorylation Nofer et al 2004
↓ apoptosis/caspases Nofer, Levkau, et al 2001
↑ TGF-β2 Norata et al 2005
PI-PLC/PKC Cell cycle entry Darbon et al 1986
P38MAPK Cox-2 synthesis Norata, Callegari, et al 2004
RhoA ↓ phopshorylation / ↓TF Viswambharan et al 2004
Transcription factors
NF-κB ↓ activity Xia et al 1999; Park et al 2003
AP-1 ↓ activity Park et al 2003
CREB ↑ activity-Cox-2 expression Norata, Callegari, et al 2004
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translocation and transactivation (Park et al 2003). Some of
the inflammatory effects of HDL may also result from the
induction of TGF-β2 expression (Norata et al 2005).
Conclusion
Endothelial dysfunction plays a key role during athero-
genesis, and HDL have been shown to protect the
endothelium through the modulation of the expression of
several genes leading to increased cell proliferation,
diminished apoptosis, increased vasorelaxation, and
decreased inflammation. Apolipoproteins, lipids, and
enzymes associated with HDL are implicated in these effects
in vitro. Injection of reconstituted HDL (Badimon et al 1990)
or ApoA-I mimetics in animal models (Chiesa et al 2002;
Chiesa and Sirtori 2002) and humans (Nissen et al 2003)
provide protection against atherosclerosis; however, the
specific effects on the endothelium have not yet been
determined.
The effects of HDL on endothelial cells depend on the
activation of several intracellular pathways. The PI3K/Akt
pathway has been implicated in many of the effects of HDL
on the endothelium; furthermore, mice overexpressing
ApoA-I present an increased Akt phosphorylation in the
arterial wall (Norata et al 2005) and mice lacking one of
the lysosphingolipid receptors show a reduced Akt
phosphorylation in the arterial wall (Nofer et al 2004).
Other signaling pathways, including ERK1/2, calcium/
calmodulin kinase, PKC, and p38MAPK, are activated by
HDL and are involved in the effects of HDL on the
endothelium.
A body of evidence thus suggests that in addition to their
role in reverse cholesterol transport, HDL positively affect
endothelial function in vitro; further studies are needed to
address the pleiotropic effects of HDL in vivo and the
molecular mechanisms involved.
Abbreviations
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